Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction

Heart

Volumn 91, Issue 12, 2005, Pages 1595-1600

  Enomoto, S ^a   Yoshiyama, Minoru ^a   Omura, T ^a   Matsumoto, R ^a   Kusuyama, T ^a   Kim, S ^a   Izumi, Y ^a   Akioka, K ^a   Iwao, H ^a   Takeuchi, K ^a   Yoshikawa, J ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DRUG VEHICLE; EPLERENONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DECELERATION; DIASTOLE; ELECTROCARDIOGRAM; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; INTERSTITIUM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RAT STRAIN; SYSTOLE;

ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; BLOTTING, NORTHERN; BODY WEIGHT; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER; HEART; HEART VENTRICLES; LIGATION; MALE; MYOCARDIAL INFARCTION; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SPIRONOLACTONE; TRANSCRIPTION FACTORS; VENTRICULAR REMODELING;

EID: 28144444256     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.046540     Document Type: Article

References (30)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
3. De Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
5. Yoshiyama M, Takeuchi K, Omura T, et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 1999;33:961-8.
6. Yoshiyama M, Omura T, Takeuchi K, et al. Angiotensin blockade inhibits increased JNKs, AP-1 and NF-kappa B DNA-binding activities in myocardial infarcted rats. J Mol Cell Cardiol 2001;33:799-810.
7. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10.
8. Patel AR, Konstam MA. Recent advances in the treatment of heart failure. Circ J 2002;66:117-21.
9. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
10. Pitt D. ACE inhibitor co-therapy in patients with heart failure: rationale for the randomized aldactone evaluation study (RALES). Eur Heart J 1995;16(suppl N):107-10.
11. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-72.
12. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
13. Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action, mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.
14. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
15. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Ore Res 1990;67:1355-64.
16. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
17. Hanatani A, Yoshiyama M, Kim S, et al. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenolypic modulation after myocardial infarction. J Mol Cell Cardiol 1995;27:1905-14.
18. Gidh-Jain M, Huang B, Jain P, et al. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J Mol Cell Cardiol 1998;30:627-37.
19. Yoshiyama M, Takeuchi K, Hanatani A, et al. Differences in expression of sarcoplasmic reticulum Ca2+-ATPase and Na+-Ca2+ exchanger genes between adjacent and remote noninfarcted myocardium after myocardial infarction. J Mol Cell Cardiol 1997;29:255-64.
20. Omura T, Yoshiyama M, Yoshida K, et al. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension 2002;39:81-6.
21. Muller DN, Dechend R, Mervaala EM, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193-201.
22. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-54.
23. Kakio T, Matsumori A, Ono K, et al. Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab Invest 2000;80:1127-36.
24. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
25. Shioi T, Matsumori A, Kihara Y, et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 1997;81:664-71.
26. Behr TM, Wang X, Aiyar N, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000;102:1315-22.
27. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003;108:2134-40.
28. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 2000;156:1865-73.
29. Takeshita K, Hayashi M, Iino S, et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004;164:449-56.
30. Sawathiparnich P, Kumar S, Vaughan DE, et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-52.